Costs and Cost Analysis

"Costs and Cost Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs.


expand / collapse Publications
This graph shows the total number of publications written about "Costs and Cost Analysis" by people in this website by year, and whether "Costs and Cost Analysis" was a major or minor topic of these publications.
Below are the most recent publications written about "Costs and Cost Analysis" by people in Profiles.
  1. Implementation of a multi-site neonatal simulation improvement program: a cost analysis. BMC Health Serv Res. 2024 May 14; 24(1):623.
    View in: PubMed
  2. Implementation and Cost Analysis of a Novel Silicosis Case-Finding Program For Mine Workers in Rural Rwanda. Glob Health Sci Pract. 2024 04 29; 12(2).
    View in: PubMed
  3. Cost Analysis of Short Messaging Service and Peer Navigator Interventions for Linking and Retaining Adults Recently Diagnosed With HIV in Care in South Africa. J Acquir Immune Defic Syndr. 2024 04 15; 95(5):417-423.
    View in: PubMed
  4. Contemporary national outcomes of hyperbaric oxygen therapy in necrotizing soft tissue infections. PLoS One. 2024; 19(3):e0300738.
    View in: PubMed
  5. Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis. Eur J Cancer. 2024 May; 202:114019.
    View in: PubMed
  6. Cost Analysis of High-Signal Approach in Otolaryngology-Head and Neck Surgery Residency. Laryngoscope. 2024 Jun; 134(6):2684-2688.
    View in: PubMed
  7. Quality of life measures and cost analysis of biologic versus synthetic mesh for ventral hernia repair: The Preventing Recurrence in Clean and Contaminated Hernias randomized clinical trial. Surgery. 2024 Apr; 175(4):1063-1070.
    View in: PubMed
  8. Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations? JCO Oncol Pract. 2024 Feb; 20(2):254-261.
    View in: PubMed
  9. Potential Avoidable Costs of Low-Value Clinical Practices in Acute Injury Care in an Integrated Canadian Provincial Trauma System. JAMA Surg. 2023 09 01; 158(9):977-979.
    View in: PubMed
  10. Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program. JAMA Intern Med. 2023 08 01; 183(8):885-889.
    View in: PubMed